High-dose methotrexate in malignant melanoma.
High-dose methotrexate was given to 28 patients with advanced malignant melanoma who had previously failed to respond to two chemotherapy protocols. There were five instances of serious, but not fatal, toxicity. One patient has had an objective response and seven patients have had stabilization of disease with an average duration of 4 months.
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy*; D002955:Leucovorin / Q000627:therapeutic use; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy*
D002955:Leucovorin; D008727:Methotrexate